Trial Profile
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2022
Price :
$35
*
At a glance
- Drugs Velmupressin (Primary) ; Desmopressin
- Indications Nocturia
- Focus Therapeutic Use
- Acronyms DAWN
- Sponsors Ferring Pharmaceuticals
- 01 Jun 2022 Results published in the Quality of Life Research
- 13 Nov 2019 Status changed from active, no longer recruiting to completed.
- 26 Aug 2019 Planned End Date changed from 31 Dec 2019 to 2 Nov 2019.